Cancer Research and Treatment

Volume 36(3); June 2004

Editorial

Cyclooxygenase-2: A Potential Target in Human Cancer: Jong-Ho Won; Cancer Res Treat. 2004;36(3):161-162. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.161

PDF PubReader ePub

Citations

Citations to this article as recorded by

Thymoquinone Induces Apoptosis in Oral Cancer Cells Through P38β Inhibition
Ehab Abdelfadil, Ya-Hsin Cheng, Da-Tian Bau, Wei-Jen Ting, Li-Mien Chen, Hsi-Hsien Hsu, Yueh-Min Lin, Ray-Jade Chen, Fu-Jenn Tsai, Chang-Hai Tsai, Chih-Yang Huang
The American Journal of Chinese Medicine.2013; 41(03): 683. CrossRef
Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer
Magdalena Halamka, Jakub Cvek, Jiri Kubes, Eva Zavadova, Pavel Kominek, Jaroslav Horacek, Ladislav Dusek, David Feltl
Oral Oncology.2011; 47(8): 763. CrossRef

6,920 View
36 Download
2 Crossref

Review Article

Lung Cancer Screening with Low-Dose Chest CT: Current Issues: Myeong Im Ahn; Cancer Res Treat. 2004;36(3):163-166. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.163

Abstract PDF PubReader ePub

Computed tomography offers many advantages over routine radiographs in screening for lung cancer, and it is clear that low-dose spiral CT screening can more frequently find considerably smaller lung cancers than previous detection tools. Recently, investigators have performed low-dose spiral CT scanning for screening of lung cancer, and have suggested that CT screening can depict lung cancers at smaller sizes and at earlier stages. With technological advances in spiral CT scanners, the detection rate of small noncalcified pulmonary nodules has markedly increased, with higher rates noted with thinner collimation of CT scanning. Unfortunately, the majority of these have proved to be benign, i.e. false positive results. If, even in part, CT features could be found to predict benign nodules without follow-up, the false-positive rate would be reduced, and consequently, the cost, emotional stress, radiation dose, morbidity and mortality associated with interventional procedures would also be reduced. There have been several studies trying to establish reliable CT features for benign lesions in small pulmonary nodules and to determine their outcome. Although these efforts have not completely resolved the issue of false positive results, it is expected that lessons will be learnt on how to manage these small nodules through experience with screening in the near future. Because pulmonary nodules on CT are much more common in Korea than in western countries, the management algorithm for screening CT-detected nodules should be modified according to different circumstances, with consensus among related physicians and radiologists. In addition, to enhance patient care and avoid misunderstanding of inherent limitation of CT screening by the screening subjects, physicians, hospital managers as well as radiologists should provide proper information regarding CT screening to the screenees.

Citations

Citations to this article as recorded by

Overuse of CT and MRI in paediatric emergency departments
Orly Ohana, Shelly Soffer, Eyal Zimlichman, Eyal Klang
The British Journal of Radiology.2018;[Epub] CrossRef
Radiological Report of Pilot Study for the Korean Lung Cancer Screening (K-LUCAS) Project: Feasibility of Implementing Lung Imaging Reporting and Data System
Ji Won Lee, Hyae Young Kim, Jin Mo Goo, Eun Young Kim, Soo Jung Lee, Tae Jung Kim, Yeol Kim, Juntae Lim
Korean Journal of Radiology.2018; 19(4): 803. CrossRef
Screening for Early Detection of Cancers II
Hong Gwan Seo
Journal of the Korean Medical Association.2006; 49(6): 515. CrossRef

7,868 View
47 Download
3 Crossref

Original Articles

Expression of c-kit and p53 in Non-small Cell Lung Cancers: Jinyoung Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Sung Whan Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Hoon-Kyo Kim; Cancer Res Treat. 2004;36(3):167-172. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.167

Abstract PDF PubReader ePub

Purpose

Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data.

Materials and Methods

Paraffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti-p53, anti-VEGF and anti-cd34 antibodies.

Results

c-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006).

Conclusion

It is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.

Citations

Citations to this article as recorded by

Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
Ying Su, Ru Chen, Zhongcheng Han, Rong Xu, Lili Ma, Reyina Wufuli, Hongbo Liu, Fang Wang, Lei Ma, Rui Chen, Jiang Liu
Pathobiology.2021; 88(4): 267. CrossRef
A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
Ernest Osei, Julia Lumini, Dinindu Gunasekara, Beverley Osei, Akua Asare, Raymond Laflamme
Journal of Radiotherapy in Practice.2020; 19(4): 370. CrossRef
Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression
Mi Zhang, Jing Liang, Shi-Kun Jiang, Ling Xu, Yan-Ling Wu, Annoor Awadasseid, Xiao-Yin Zhao, Xu-Qiong Xiong, Hiroshi Sugiyama, Wen Zhang
European Journal of Medicinal Chemistry.2020; 207: 112704. CrossRef
Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer
HUI XIAO, JUAN WANG, YANAN LIU, LI LI
Oncology Letters.2014; 8(2): 582. CrossRef
Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
Misun Park, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim
Clinical Cancer Research.2013; 19(18): 4961. CrossRef

9,160 View
62 Download
5 Crossref

Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: Nam-Su Lee, Jae-Ho Byun, Sang-Byung Bae, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park; Cancer Res Treat. 2004;36(3):173-177. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.173

Abstract PDF PubReader ePub

Purpose

The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC.

Materials and Methods

Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m², infusion over 30 minutes on days 1, followed by a gemcitabine, 1,250 mg/m², infusion over 30 minutes on days 1 and 8 every 3 weeks.

Results

The median age of the patients was 64 years (range: 27~75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1~15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8~22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months.

Conclusion

In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC.

Citations

Citations to this article as recorded by

Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells
Jeong-Hun Lee, Kyung-Sook Chung, Hwi-Ho Lee, Dohyeong Ko, Minji Kang, Ho Yoo, JooHoon Ahn, Jae Yeol Lee, Kyung-Tae Lee
Biomedicine & Pharmacotherapy.2021; 142: 111961. CrossRef
Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere
Dean G. Campelj, Craig A. Goodman, Emma Rybalka
Cancers.2021; 13(14): 3615. CrossRef
New Strategies for Safe Cancer Therapy Using Electrospun Nanofibers: A Short Review
Mohsen Doostmohammadi, Hamid Forootanfar, Seeram Ramakrishna
Mini-Reviews in Medicinal Chemistry.2020; 20(13): 1272. CrossRef
Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer
Louis T. Curtis, Victor H. van Berkel, Hermann B. Frieboes
Journal of Theoretical Biology.2018; 448: 38. CrossRef
Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials
Zheng Xiao, Chengqiong Wang, Ling Chen, Xuemei Tang, Lianhong Li, Nana Li, Jing Li, Qihai Gong, Fushan Tang, Jihong Feng, Xiaofei Li
Oncotarget.2017; 8(1): 1329. CrossRef
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma
Nadine Houédé, Laura Dupuy, Aude Fléchon, Philippe Beuzeboc, Gwenaëlle Gravis, Brigitte Laguerre, Christine Théodore, Stéphane Culine, Thomas Filleron, Christine Chevreau
BJU International.2016; 117(3): 444. CrossRef
Ototoxin-induced cellular damage in neuromasts disrupts lateral line function in larval zebrafish
Lauren M.J. Buck, Matthew J. Winter, William S. Redfern, Tanya T. Whitfield
Hearing Research.2012; 284(1-2): 67. CrossRef

9,092 View
45 Download
7 Crossref

Predictive Value of Preoperative Serum CEA, CA19-9 and CA125 Levels for Peritoneal Metastasis in Patients with Gastric Carcinoma: Gun Ick Hwang, Chang Hak Yoo, Byung Ho Sohn, Jun Ho Shin, Yong Lai Park, Heung Dai Kim, Yong Shin Kim, Won Kon Han, Won Kil Pae; Cancer Res Treat. 2004;36(3):178-181. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.178

Abstract PDF PubReader ePub

Purpose

Peritoneal metastasis is a crucial factor for the prognosis in gastric cancer, but its diagnosis is difficult before laparotomy. This study analyzed the usefulness of diagnostic imaging and various tumor markers in the detection of peritoneal metastasis in gastric cancer.

Materials and Methods

The sera from 768 patients with gastric cancer were measured for CEA, CA19-9 and CA125 levels using a commercial immunoradiometric assay. All the patients underwent diagnostic imaging with computed tomography (CT) and ultrasound (US) before laparotomy.

Results

Preoperative levels of CEA, CA19-9 and CA125 were above the cut-off levels in 15.4%, 8.7% and 5.7% of all cases, respectively. Eighty-eight patients were diagnosed with peritoneal metastasis by laparotomy. CT and US revealed peritoneal dissemination in 15 of 88 patients (17%). Among the three tumor markers, CA19-9 and CA125 showed similar detection rates of peritoneal metastasis (37.5% and 38.6%, respectively). In particular, the serum CA125 levels showed the best sensitivity (38.6%), specificity (98.4%), and diagnostic accuracy (91.5%), and the highest odd ratio (24.46, 95% CI: 11.17~53.57) for predicting peritoneal metastasis among the markers tested. CEA did not add significant predictive information (p=0.471).

Conclusion

Preoperative serum CA19-9 and CA125 levels may provide a predictable value in determining peritoneal metastasis in patients with gastric cancer.

Citations

Citations to this article as recorded by

Prognostic significance of serum tumor markers in various pathologic subtypes of gastric cancer
Chuhong Pang, Yubo Ma, Wenyi Shi, Mengli Zi, Jinxia Chen, Chen Liang, Xiao Li, Zhuo Liu, Yian Du
Journal of Gastrointestinal Surgery.2024; 28(5): 694. CrossRef
Development of Panel of Three-Dimensional Biomarkers to Identify Gastric Carcinoma and Precancerous Lesions of the Stomach - An Analytical Cross-Sectional Study
Sandhya Karra, Ramanan Sinduja, Balakrishnan Gurushankari, T. P. Elamurugan, Thulasingam Mahalakshmy, Vikram Kate, Nivedita Nanda, Nachiappa Ganesh Rajesh, Murugesan Rajeswari, Ruben Raj, Gomathi Shankar
Indian Journal of Clinical Biochemistry.2024;[Epub] CrossRef
Usefulness of Diagnostic Staging Laparoscopy for Advanced Gastric Cancer
Kozo Yoshikawa, Mitsuo Shimada, Jun Higashijima, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Shohei Eto, Toshiaki Yoshimoto
The American Surgeon™.2023; 89(4): 685. CrossRef
Intraoperative Pathological Evaluation of Suspicious Peritoneal Nodules for Surgical Decision-making in Gastric Cancer
Chen Wang, Junjie Zhao, Jie Sun, Chenyu Tian, Zhiqiang Dai, Jingdong Liu, Chengbo Ji, Dan Liu, Xuefei Wang, Haojie Li, Yihong Sun
Journal of Gastrointestinal Surgery.2023; 27(8): 1545. CrossRef
Development and validation of a CT radiomics and clinical feature model to predict omental metastases for locally advanced gastric cancer
Ahao Wu, Changlei Wu, Qingwen Zeng, Yi Cao, Xufeng Shu, Lianghua Luo, Zongfeng Feng, Yi Tu, Zhigang Jie, Yanyan Zhu, Fuqing Zhou, Ya Huang, Zhengrong Li
Scientific Reports.2023;[Epub] CrossRef
Nomogram for predicting overall survival after curative gastrectomy using inflammatory, nutritional and pathological factors
Qi Wang, Qiang Zhang, Jiankang Zhu, Linchuan Li, Runzhi Zeng, Huanxin Ding, Zhenmin Li, Tianyi Feng, Ruiqi Hao, Guangyong Zhang
Clinical and Translational Oncology.2023; 26(4): 1001. CrossRef
Does CA 125 Predict Peritoneal Dissemination in Patients with Gastric Cancer?
Murat Güner, Tayfun Kaya, Cengiz Aydın
Indian Journal of Surgery.2022; 84(4): 779. CrossRef
Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer
Jiang Huang, Yidi Chen, Yuying Zhang, Jinhuan Xie, Yiqiong Liang, Wenzhao Yuan, Ting Zhou, Ruizhi Gao, Rong Wen, Yuwei Xia, Liling Long
Abdominal Radiology.2022; 47(1): 66. CrossRef
Clinical effect of 64-row spiral CT combined with multiple tumor markers in the diagnosis of gastric cancer and its effect on accuracy
Libo YU, Lei LI, Meiying YU, Jun CHEN
Minerva Medica.2022;[Epub] CrossRef
Investigation of serum markers of esophageal squamous cell carcinoma based on machine learning methods
Zhifeng Ma, Ting Zhu, Haiyong Wang, Bin Wang, Linhai Fu, Guangmao Yu
The Journal of Biochemistry.2022; 172(1): 29. CrossRef
Construction of a Nomogram Model for Predicting Peritoneal Dissemination in Gastric Cancer Based on Clinicopathologic Features and Preoperative Serum Tumor Markers
Dandan Bao, Zhangwei Yang, Senrui Chen, Keqin Li, Yiren Hu
Frontiers in Oncology.2022;[Epub] CrossRef
Novel CT based clinical nomogram comparable to radiomics model for identification of occult peritoneal metastasis in advanced gastric cancer
Lili Wang, Peng Lv, Zhen Xue, Lihong Chen, Bin Zheng, Guifang Lin, Weiwen Lin, Jingming Chen, Jiangao Xie, Qing Duan, Jun Lu
European Journal of Surgical Oncology.2022; 48(10): 2166. CrossRef
Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy
Zhemin Li, Guangmin Guan, Zining Liu, Jiazheng Li, Xiangji Ying, Fei Shan, Ziyu Li
Frontiers in Surgery.2022;[Epub] CrossRef
Collagen Family as Promising Biomarkers and Therapeutic Targets in Cancer
Laura Necula, Lilia Matei, Denisa Dragu, Ioana Pitica, Ana Neagu, Coralia Bleotu, Carmen C. Diaconu, Mihaela Chivu-Economescu
International Journal of Molecular Sciences.2022; 23(20): 12415. CrossRef
Risk factors associated with peritoneal carcinomatosis of gastric cancer in staging laparoscopy: A systematic review and meta-analysis
Guangmin Guan, Zhemin Li, Qi Wang, Xiangji Ying, Fei Shan, Ziyu Li
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Applications of Liquid Biopsy in Gastric Cancer
Mihaela Chivu-Economescu, Laura Necula, Lilia Matei, Denisa Dragu, Coralia Bleotu, Carmen C. Diaconu
Frontiers in Medicine.2021;[Epub] CrossRef
A Novel Nomogram Integrated with Inflammation-Based Factors to Predict the Prognosis of Gastric Cancer Patients
Xueping Wang, Minjie Mao, Shihao Zhu, Shan Xing, Yiling Song, Lin Zhang, Peidong Chi
Advances in Therapy.2020; 37(6): 2902. CrossRef
Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma

Yao Huang, Jianxing Zeng, Teng Liu, Xinju Lin, Pengfei Guo, Jinhua Zeng, Weiping Zhou, Jingfeng Liu
OncoTargets and Therapy.2020; Volume 13: 4559. CrossRef
Predicting Peritoneal Dissemination of Gastric Cancer in the Era of Precision Medicine: Molecular Characterization and Biomarkers
Yanyan Chen, Quan Zhou, Haiyong Wang, Wei Zhuo, Yongfeng Ding, Jun Lu, Guanghao Wu, Nong Xu, Lisong Teng
Cancers.2020; 12(8): 2236. CrossRef
A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer
Junjie Zhao, Ruihuan Qin, Hao Chen, Yupeng Yang, Wenjun Qin, Jing Han, Xuefei Wang, Shifang Ren, Yihong Sun, Jianxin Gu
Clinical Proteomics.2020;[Epub] CrossRef
Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading
Bayazid Ghaderi, Hamoon Moghbel, Nasrin Daneshkhah, Asrin Babahajian, Farshad Sheikhesmaeili
Journal of Gastrointestinal Cancer.2019; 50(3): 525. CrossRef
Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers
Caleb Harris, Vikas Ostwal, Dilip Harindran Vallathol, Rohit Dusane, Sarika Mandavkar, Shraddha Patkar, Anant Ramaswamy, Shailesh V. Shrikhande
South Asian Journal of Cancer.2019; 08(03): 166. CrossRef
Clinical Significance of Serum CA125, CA19-9, CA72-4, and Fibrinogen-to-Lymphocyte Ratio in Gastric Cancer With Peritoneal Dissemination
Chao Huang, Zitao Liu, Li Xiao, Yongqiang Xia, Jun Huang, Hongliang Luo, Zhen Zong, Zhengming Zhu
Frontiers in Oncology.2019;[Epub] CrossRef
A new score for screening of malnutrition in patients with inoperable gastric adenocarcinoma
Ali Esfahani, Mohammad Hossein Somi, Mohammad Asghari Jafarabadi, Alireza Ostadrahimi, Mousa Ghayour Nahand, Zahra Fathifar, Akram Doostzadeh, Zohreh Ghoreishi
Japanese Journal of Clinical Oncology.2017; 47(6): 475. CrossRef
Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer
Xiao-dong Chen, Chen-chen Mao, Rui-sen Wu, Wei-teng Zhang, Ji Lin, Xiang-wei Sun, Chu-huai Chi, Neng Lou, Peng-fei Wang, Xian Shen, Guan-bao Zhu, Shu-rong Shen, Valli De Re
PLOS ONE.2017; 12(4): e0175074. CrossRef
Tumor volume increases the predictive accuracy of prognosis for gastric cancer: A retrospective cohort study of 3409 patients
Zhen Liu, Peng Gao, Shushang Liu, Gaozan Zheng, Jianjun Yang, Li Sun, Liu Hong, Daiming Fan, Hongwei Zhang, Fan Feng
Oncotarget.2017; 8(12): 18968. CrossRef
Peritoneal recurrence in gastric cancer following curative resection can be predicted by postoperative but not preoperative biomarkers: a single-institution study of 320 cases
Fan Wu, Chunmei Shi, Riping Wu, Zhiqing Huang, Qiang Chen
Oncotarget.2017; 8(44): 78120. CrossRef
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options
Nina Sluiter, Erienne de Cuba, Riom Kwakman, Geert Kazemier, Gerrit Meijer, Elisabeth Atie te Velde
Clinical & Experimental Metastasis.2016; 33(5): 401. CrossRef
The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)
LIANG LIU, JINFENG XIANG, RUFU CHEN, DELIANG FU, DEFEI HONG, JIHUI HAO, YIXIONG LI, JIANGTAO LI, SHENGPING LI, YIPING MOU, GANG MAI, QUANXING NI, LI PENG, RENYI QIN, HONGGANG QIAN, CHENGHAO SHAO, BEI SUN, YONGWEI SUN, MIN TAO, BOLE TIAN, HONGXIA WANG, JIA
International Journal of Oncology.2016; 48(3): 900. CrossRef
Clinical Significance of CA125 Level with Clinicopathological Variables and Peritoneal Dissemination in Patients with Gastric Carcinoma
Laila Shirin
Gastroenterology & Hepatology: Open Access.2016;[Epub] CrossRef
Prognostic values of normal preoperative serum cancer markers for gastric cancer
Fan Feng, Li Sun, Zhen Liu, Shushang Liu, Gaozan Zheng, Guanghui Xu, Man Guo, Xiao Lian, Daiming Fan, Hongwei Zhang
Oncotarget.2016; 7(36): 58459. CrossRef
Marqueurs sériques
M. Vallée, D. Tougeron
EMC - Gastro-entérologie.2016; 33(4): 1. CrossRef
Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients
Dae Hoon Kim
World Journal of Gastroenterology.2015; 21(4): 1216. CrossRef
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association
Hideaki Shimada, Tamaki Noie, Manabu Ohashi, Koji Oba, Yutaka Takahashi
Gastric Cancer.2014; 17(1): 26. CrossRef
Combined use of lysyl oxidase, carcino-embryonic antigen, and carbohydrate antigens improves the sensitivity of biomarkers in predicting lymph node metastasis and peritoneal metastasis in gastric cancer
Hao Lai, Qinwen Jin, Yuan Lin, Xianwei Mo, Bo Li, Ke He, Jiansi Chen
Tumor Biology.2014; 35(10): 10547. CrossRef
Combined Detection of CEA, CA 19-9, CA 242 and CA 50 in the Diagnosis and Prognosis of Resectable Gastric Cancer
Shu-Bo Tian, Jian-Chun Yu, Wei-Ming Kang, Zhi-Qiang Ma, Xin Ye, Zhan-Jiang Cao, Chao Yan
Asian Pacific Journal of Cancer Prevention.2014; 15(15): 6295. CrossRef
Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination
Shigenobu Emoto, Hironori Ishigami, Hiroharu Yamashita, Hironori Yamaguchi, Shoichi Kaisaki, Joji Kitayama
Gastric Cancer.2012; 15(2): 154. CrossRef
Pilot Feasibility Study of Neoadjuvant Chemoradiotherapy with S-1 in Patients with Locally Advanced Gastric Cancer Featuring Adjacent Tissue Invasion or JGCA Bulky N2 Lymph Node Metastases
Tatsushi Inoue, Shinichi Yachida, Hisashi Usuki, Tomoki Kimura, Masanobu Hagiike, Keiichi Okano, Yasuyuki Suzuki
Annals of Surgical Oncology.2012; 19(9): 2937. CrossRef
Serum levels of CA19-9 may be as an indicator for metastases in patients with non-small cell lung cancer
Xing’an Liu, Guoyong Shan, Song Zhang, Kaijian Lei
The Chinese-German Journal of Clinical Oncology.2011; 10(12): 692. CrossRef
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
HanByoul Cho, Hye Won Hur, Sang Wun Kim, Sung Hoon Kim, Jae Hoon Kim, Young Tae Kim, Kook Lee
Cancer Immunology, Immunotherapy.2009; 58(1): 15. CrossRef

11,366 View
78 Download
40 Crossref

Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study: Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon; Cancer Res Treat. 2004;36(3):182-186. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.182

Abstract PDF PubReader ePub

Purpose

To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.

Materials and Methods

Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m² iv on day 1, heptaplatin 400 mg/m² iv on day 2 and 5-fluorouracil 800 mg/m² on day 2~4 were administered and the regimen was repeated every 3 weeks.

Results

The median age of the patients was 60 years (range: 32~74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26~8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48~6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26~17.44). A median of 3 cycles (range: 1~7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life-threatening complication of pneumonia.

Conclusion

The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed.

Citations

Citations to this article as recorded by

Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases
Dobrina Tsvetkova, Stefka Ivanova
Molecules.2022; 27(8): 2466. CrossRef
Synthesis of novel heptaplatin derivatives and evaluation of their ability to inhibit proliferation of cancer cell lines
W. Xu, D. C. Wang
Russian Journal of General Chemistry.2016; 86(4): 939. CrossRef

8,055 View
51 Download
2 Crossref

Expression of Cyclooxygenase (COX)-2 as a Prognostic Factor in Nasopharyngeal Cancer: Kyubo Kim, Hong-Gyun Wu, Suk Won Park, Chong Jai Kim, Charn Il Park; Cancer Res Treat. 2004;36(3):187-191. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.187

Abstract PDF PubReader ePub

Purpose

To evaluate the relationship between treatment failure and COX-2 expression in nasopharyngeal cancer patients treated with chemotherapy and radiotherapy.

Materials and Methods

The subjects of this study were 22 nasopharyngeal cancer patients. The patients were treated with neoadjuvant chemotherapy, followed by radiotherapy, or with radiotherapy alone. The formalin-fixed, paraffin-embedded tissues of 11 patients who developed a locoregional recurrence (n=7) or distant metastasis (n=4) were compared with those of 11 disease free patients. Prognostic factors, including histological type, stage, radiation dose and chemotherapy, were well balanced between the two groups. The COX-2 expression was determined immunohistochemically.

Results

COX-2 expression was stronger in the patients with a locoregional recurrence or distant metastasis than in those free of disease. The COX-2 distribution scores of the control group were as follows: 0 in 7, 1 in 2 and 2 in 2 patients. In the recurrence group, the scores were as follows; 0 in 3, 1 in 1, 2 in 2 and 3 in 5 patients. COX-2 expression was shown to have a statistically significant influence on the treatment failure by the Mann-Whitney U test (p=0.024) and Mantel-Haenszel Chi-Square test (p=0.018). It also significantly influenced the treatment failure when an analysis was performed within patients with a undifferentiated histology (p=0.039 by the Mann-Whitney U test, p=0.037 by the Mantel-Haenszel Chi-Square test).

Conclusion

COX-2 expression is believed to be one of the important factors associated with a locoregional recurrence or distant metastasis.

Citations

Citations to this article as recorded by

Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis
Bin Yang, Lin Jia, Qiaojuan Guo, Hui Ren, Yanping Hu, Tao Xie
Oncotarget.2016; 7(30): 47265. CrossRef
Prognostic significance of expression of cyclooxygenase‐2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma
Jianji Pan, Tianlan Tang, Luying Xu, Jiade J. Lu, Senan Lin, Sufang Qiu, Gang Chen, Ivan W. K. Tham
Head & Neck.2013; 35(9): 1238. CrossRef
Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy
Yeon‐Joo Kim, Heounjeong Go, Hong‐Gyun Wu, Yoon Kyung Jeon, Suk Won Park, Seung Hee Lee
Head & Neck.2011; 33(10): 1458. CrossRef
Immunohistochemical Study to Evaluate the Prognostic Significance of Four Biomolecular Markers in Radiotherapy of Nasopharyngeal Carcinoma
Yeon-Joo Kim, Seung Hee Lee, Hong-Gyun Wu, Heounjeong Go, Yoon Kyung Jeon
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2010; 28(2): 57. CrossRef

9,211 View
54 Download
4 Crossref

Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma: Jin-Hee Ahn, Sung-Bae Kim, Sei-Hyun Ahn, Gyung-Yub Gong, Myung-Ju Ahn, Yoon-Koo Kang, Jung-Shin Lee, Woo Kun Kim; Cancer Res Treat. 2004;36(3):192-198. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.192

Abstract PDF PubReader ePub

Purpose

To determine whether COX-2 expression is associated with clinicopathological parameters, including c-erb-B2 overexpression and angiogenesis, and the disease-free survival of patients with operable breast cancer.

Materials and Methods

Paraffin-embedded tissue samples were selected from 205 patients surgically resected for breast cancer, between 1991 and 1997, and followed-up for at least 4 years. Samples were immunohistochemically stained with antibodies to COX-2, c-erb-B2 and CD34.

Results

COX-2 and c-erb-B2 expressions were detected in 118/205 (57.6%) and 58/205 (28.3%) patients, respectively. COX-2 expression was significantly higher in c-erb-B2 positive than c-erb-B2 negative tumors (75.9% vs. 49.7%, p-value 0.001). COX-2 expression was positively correlated with microvessel count (13.3±8.0 vs. 6.6±7.0, p-value 0.050), but not with other clinicopathological characteristics, including tumor size, involved axil lary lymph nodes and estrogen or progesterone receptor status. Although COX-2 expression itself was not a prognostic marker, breast cancer patients with tumors that co-expressed both COX-2 and c-erb-B2 had a poorer 5-year disease-free survival rate than those that did not (60.2% vs. 78.3%, p-value 0.0527).

Conclusion

Our data suggest that COX-2 expression occurs frequently in c-erb-B2 positive breast cancer, and co-expression of COX-2 and c-erb-B2 may be a useful prognostic marker in patients with operable breast cancer.

Citations

Citations to this article as recorded by

The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old
Eun Seog Kim, Doo Ho Choi, So Young Jin, Dong Wha Lee, Hee Sook Park, Min Hyuk Lee, Jong Ho Won, Yong Ho Kim, Kyu Taek Lee, Sung Yong Kim
The Journal of the Korean Society for Therapeutic Radiology and Oncology.2008; 26(1): 45. CrossRef
Expression of Cyclooxygenase-2 in Human Breast Cancer: Relationship with HER-2/neu and other Clinicopathological Prognostic Factors
Eunmi Nam, Soon Nam Lee, Seock-Ah Im, Do-Yeun Kim, Kyoung Eun Lee, Sun Hee Sung
Cancer Research and Treatment.2005; 37(3): 165. CrossRef
Cyclooxygenase-2: A Potential Target in Human Cancer
Jong-Ho Won
Cancer Research and Treatment.2004; 36(3): 161. CrossRef

9,687 View
43 Download
3 Crossref

The Efficacy of a Modified Chronomodulated Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin in Advanced Colorectal Cancer (Preliminary Data): Ji Young Park, Si-Young Kim, Jae Jin Lee, Hwi Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2004;36(3):199-204. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.199

Abstract PDF PubReader ePub

Purpose

To determine the efficacy and tolerability of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in the treatment of advanced colorectal cancer.

Materials and Methods

Sixteen patients with relapsed or metastatic colorectal cancer were treated with an intravenous infusion of oxaliplatin 25 mg/m², 5-FU 700 mg/m² and leucovorin 20 mg/m² on days 1 to 5. The infusion of oxaliplatin was chronomodulated with a peak delivery rate at 16:00 p.m., with 5-FU infused constantly overnight. Each course was repeated every 21 days.

Results

The response rate was 38.5% (95% confidence interval [CI], 13.9% to 68.4%) in the 13 measurable patients, including 1 complete response (7.7%) and 4 partial responses (30.8%). Five patients (38.5%) had a stable disease and 3 (23.0%) a progressive disease. Three patients without a measurable lesion had improved status. The median time to progression and overall survival were 29 weeks and 85 weeks, respectively. Grade 3 thrombocytopenia occurred in 2.5% (2 cycles) and grade 3 vomiting in 12.5% (2 patients). Anorexia, stomatitis, diarrhea, pruritus, alopecia and peripheral neuropathy were mild and tolerable.

Conclusion

The modified chronomodulated infusion of oxaliplatin, 5-FU and leucovorin is effective and tolerable, but the number of patients was too small. Further study will be needed to confirm the efficacy of this regimen with a larger population of patients.

Citations

Citations to this article as recorded by

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
Cancer Research and Treatment.2005; 37(5): 284. CrossRef

9,532 View
45 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Previous issues